Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

A population based perspective on children and youth with brain tumours

Authors: Vincy Chan, Jason D. Pole, Robert E. Mann, Angela Colantonio

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

There is currently no active surveillance of metastatic and non-malignant brain tumours in Canada as well as data on the health service use of children and youth with brain tumours. The objective of this study was to identify pediatric primary, metastatic, benign, and unspecified brain tumours in Ontario, Canada and to describe their health service use from a population based perspective.

Methods

The population based healthcare administrative databases National Ambulatory Care Reporting System and the Discharge Abstract Database were used. Patients with malignant (primary and metastatic), benign, and unspecified brain tumours in acute care between fiscal year 2003/04 and 2009/10 were identified using specified International Classification of Diseases version ten codes.

Results

Between fiscal year 2003/04 and 2009/10, there were 4022 brain tumour episodes of care (18.4 per 100,000 children and youth). Malignant brain tumors had the highest rates of episodes of care (14.9 times higher than that of benign and 5.7 times higher than that of unspecified brain tumours). Compared to patients with malignant brain tumours, those with benign brain tumours spent a longer period of time in acute care (p < .05) and patients with unspecified brain tumours stayed in the intensive care units for a longer period of time (p < .0001) with a lower proportion were discharged home (p < .0001).

Conclusion

Despite higher rates of malignant brain tumour episodes of care, patients with benign and unspecified brain tumours also use acute care services and post-acute services that are currently not taken into account in healthcare planning and resource allocation. Active surveillance and research of metastatic and non-malignant brain tumours that can inform the planning of healthcare services and resource allocation for this population is encouraged.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
The burden of neurological diseases, disorders, and injuries in Canada. 2007, Canadian Institute for Health Information Ottawa.
5.
<Canadian-Cancer-Statistics-2014-EN.pdf > .
6.
7.
8.
Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol. 2001;3(3):152–8.PubMedPubMedCentral
9.
Caldarella A, Crocetti E, Paci E. Is the incidence of brain tumors really increasing? A population-based analysis from a cancer registry. J Neurooncol. 2011;104(2):589–94.CrossRefPubMed
10.
McCarthy BJ, Schellinger KA, Propp JM, Kruchko C, Malmer B. A case for the worldwide collection of primary benign brain tumors. Neuroepidemiology. 2009;33(3):268–75.CrossRefPubMed
11.
Nicholson HS, Nathan PC, Zebrack B, Tersak JM, Ness KK, Gurney JG, et al. Social outcomes in the childhood cancer survivor study cohort. J Clin Oncol. 2009;27(14):2390–5.CrossRefPubMedPubMedCentral
12.
Kaste SC, Marina N, Whitton J, Robison LL, Gurney JG, Ness KK, et al. Physical performance limitations in the childhood cancer survivor study cohort. J Clin Oncol. 2009;27(14):2382–9.CrossRefPubMedPubMedCentral
13.
14.
15.
Juurlink, D, Preyra C, Croxford R, Chong A, Austin P, Tu J, Laupacis A, Canadian Institute for Health Information Discharge Abstract Database: A Validation Study. Toronto, ON: Institute for Clinical Evaluative Sciences; 2006.
16.
17.
Colantonio A, Saverino C, Zagorski B, Swaine B, Lewko J, Jaglal S, et al. Hospitalizations and emergency department visits for TBI in Ontario. Can J Neurol Sci. 2010;37:783–90.CrossRefPubMed
18.
Cancer in Australia: An Overview 2012. 2012, Australian Institute of Health and Welfare & Australasian Association of Cancer Registries
19.
Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS, Ostrom QT, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 2013;15 Suppl 2:ii1–56.PubMedPubMedCentral
20.
21.
Oldenburger F, Caron HN, Voûte PA, Van Leeuwen FE, Van den Berg H, Cardous-Ubbink MC, et al. Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer. 2007;43(2):351–62.CrossRefPubMed
22.
Munce SE, Laan RV, Levy C, Parsons D, Jaglal SB. Systems analysis of community and health services for acquired brain injury in Ontario. Canada Brain Inj. 2014;28(8):1042–51.CrossRefPubMed
23.
Preen DB, Holman CD, Spilsbury K, Semmens JB, Brameld KJ. Length of comorbidity lookback period affected regression model performance of administrative health data. J Clin Epidemiol. 2006;59(9):940–6.CrossRefPubMed
24.
Metadata
Title
A population based perspective on children and youth with brain tumours
Authors
Vincy Chan
Jason D. Pole
Robert E. Mann
Angela Colantonio
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-2016-0

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker

Research article

Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

Research article

Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer

Research article

The Danish cancer pathway for patients with serious non-specific symptoms and signs of cancer–a cross-sectional study of patient characteristics and cancer probability

Research article

Apparent diffusion coefficient measurement by diffusion weighted magnetic resonance imaging is a useful tool in differentiating renal tumors

Research article

Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits